YARW Yarrow Bioscience, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1566044 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.1%
TTM net income YoY-35.6%
TTM EPS YoY-1,140.7%
Revenue 3-yr CAGR-12.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,949.6%
Net margin-8,097.7%
FCF margin—
EBITDA margin—
Returns
ROE-67.8%
ROA-58.7%
ROIC (approx.)-108.4%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $570,000 | $501,000 | $424,000 | $477,000 | $931,000 |
| Cost of revenue | — | — | — | — | $3.35M |
| Gross profit | — | — | — | — | -$2.42M |
| R&D expense | $19.24M | $30.95M | $16.31M | $18.39M | $19.54M |
| SG&A expense | $11.08M | $13.19M | $13.38M | $16.39M | $20.30M |
| Operating income | -$29.75M | -$43.64M | -$29.26M | -$34.30M | -$38.91M |
| Interest expense | — | — | — | $0 | $5.61M |
| Pretax income | -$26.73M | -$39.80M | -$27.87M | -$33.93M | -$44.66M |
| Income tax | $4,000 | $4,000 | $0 | $13,000 | -$448,000 |
| Net income | -$26.48M | -$39.83M | -$28.45M | -$23.21M | -$73.33M |
| EBITDA | -$29.73M | -$43.63M | -$29.26M | -$34.22M | -$38.80M |
| EPS (basic) | -0.62 | -0.93 | -2.78 | -7.28 | -25.64 |
| EPS (diluted) | -0.62 | -0.93 | -2.78 | -7.28 | -25.64 |
| Weighted avg. shares (diluted) | 42.77M | 42.59M | 10.27M | 3.19M | 2.86M |
| Balance sheet | |||||
| Cash & equivalents | $99.99M | $19.93M | $30.67M | $30.98M | $42.85M |
| Short-term investments | $4.98M | $41.59M | $62.63M | $0 | $0 |
| Receivables | — | — | — | $173,000 | $7.58M |
| Inventory | — | — | — | — | $7.29M |
| Current assets | $100.00M | $64.44M | $95.96M | $38.27M | $63.19M |
| PP&E, net | $0 | $113,000 | $0 | $0 | $354,000 |
| Total assets | $100.41M | $66.91M | $97.69M | $40.76M | $67.05M |
| Current liabilities | $71.55M | $14.82M | $7.54M | $9.35M | $18.41M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 |
| Total debt | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $71.55M | $14.82M | $8.95M | $9.35M | $18.41M |
| Shareholders' equity | -$70.99M | $52.09M | $88.73M | $31.20M | $48.64M |
| Net debt | -$99.99M | -$19.93M | -$30.67M | -$30.98M | -$42.85M |
| Shares outstanding | 3.05M | 14.83M | 14.10M | 3.23M | 2.98M |
| Cash flow statement | |||||
| Operating cash flow | -$33.12M | -$33.97M | -$25.34M | -$29.20M | -$56.37M |
| Capital expenditure | $0 | $117,000 | $0 | — | $0 |
| Free cash flow | -$33.12M | -$34.09M | -$25.34M | — | -$56.37M |
| Investing cash flow | $37.37M | $23.36M | -$57.35M | $15.67M | $1.03M |
| Financing cash flow | -$143,000 | -$141,000 | $82.39M | $1.65M | $39.78M |
| Depreciation & amortization | $23,000 | $4,000 | $0 | $72,000 | $109,000 |
| Stock-based compensation | $2.31M | $3.30M | $3.31M | $4.30M | $8.08M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.